Latest Articles
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat
Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance
Published: Feb. 27, 2026, 4:47 p.m.
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView
Published: Feb. 27, 2026, 3:34 p.m.
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks
Published: Feb. 27, 2026, 3:24 p.m.
Advancing support for endometriosis and menstrual wellbeing - GOV.UK
Advancing support for endometriosis and menstrual wellbeing GOV.UK
Published: Feb. 27, 2026, 3:11 p.m.
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion - TradingView
ACRV: ACR-368 shows high efficacy and safety in serous endometrial cancer, supporting global expansion TradingView
Published: Feb. 27, 2026, 2:50 p.m.
13 Years After Diagnosis, I Still Feel Unprotected As An Endometriosis Sufferer - HuffPost UK
13 Years After Diagnosis, I Still Feel Unprotected As An Endometriosis Sufferer HuffPost UK
Published: Feb. 27, 2026, 2:48 p.m.
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer - Stock Titan
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer Stock Titan
Published: Feb. 27, 2026, 2 p.m.
Sanju Pal's endometriosis case: How painful periods impact workplace performances, IVF specialist weighs... - Moneycontrol.com
Sanju Pal's endometriosis case: How painful periods impact workplace performances, IVF specialist weighs... Moneycontrol.com
Published: Feb. 27, 2026, 1:35 p.m.
Endometriosis Treatment Market to Reach $5.64 Billion by 2033 at 5.4% CAGR – Strategic Revenue Insights (SRI) - industrytoday.co.uk
Endometriosis Treatment Market to Reach $5.64 Billion by 2033 at 5.4% CAGR – Strategic Revenue Insights (SRI) industrytoday.co.uk
Published: Feb. 27, 2026, 9:31 a.m.
Link copied to clipboard!